Media Releases
 
 peptide and neuropeptide  WHAT'S NEW
 peptide and neuropeptide  ONLINE CATALOG
 peptide and neuropeptide  CUSTOM SYNTHESIS
 peptide and neuropeptide  ANALYTICAL DATA SHEET (ADS)
 peptide and neuropeptide  SERVICES
 peptide and neuropeptide  TECHNICAL LIBRARY
 peptide and neuropeptide  DOCUMENTS
 peptide and neuropeptide  SITEMAP
 peptide and neuropeptide  JOBS
 peptide and neuropeptide  CONTACT
   BOOKMARK & SHARE
  © Bachem Holding AG
October 6, 2000    
 
Bubendorf, October 6, 2000

Bachem Enlarges its Management Team

Beginning January 1, 2001, Rolf Nyfeler, former head of the Bachem Group's Bubendorf headquarters, will become the Group's Chief Operating Officer (COO) and will, as Chairman of Group Management, assume responsibility for overseeing operations.

Succeeding Nyfeler as head of the Swiss headquarters will be Thomas Früh, previously Chief Operating Officer (COO) of Bachem Bioscience Inc. in Philadelphia.

Peter Grogg, founder of the Bachem Group, will, as President of the Board and Chief Executive Officer (CEO), maintain his responsibility for the Group's strategic management.

Bachem is an independent, technology-based company specializing in the development of manufacturing processes for the production of innovative biochemical and pharmaceutical compounds.

With headquarters in Switzerland and affiliates in Europe and the US, Bachem operates on a global scale and holds a leading position in its field.



For further information please contact:

Bachem AG
Jörg Stumpf
Hauptstrasse 144
CH-4416 Bubendorf
Telephone +41-61-931 23 33
Fax +41-61-931 25 49

 
        Deutsche Version